Full-Time

Associate Statistical Project Leader

I&I Biostatistics

Posted on 6/5/2025

Deadline 7/15/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Mid

Frankfurt, Germany + 1 more

More locations: Berlin, Germany

Hybrid position; specific in-office days not mentioned.

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
SAS
R
Data Analysis
Requirements
  • PhD/MS in statistics or related discipline
  • At least 3 years of pharmaceutical experience in clinical development, including late phase
  • Broad knowledge and good understanding of advanced statistical concepts and techniques
  • Able to do advanced statistical analyses using SAS or R
  • Demonstrated strong interpersonal and communication skills
  • Main Languages: English (plus French or German)
Responsibilities
  • Provide high quality input into the design of the clinical study, the setup and conduct of the study
  • Accountable for all statistical deliverables related to the study
  • Oversee execution of the statistical analyses according to the statistical analysis plan
  • Prepare statistical methods & provide statistical insight into interpretation and discussion of results sections for the clinical study report and/or publications
  • Propose, prepare and perform exploratory data analyses, ad-hoc analyses as relevant for the study or project objectives
  • Provide technical guidance to junior staff
  • Plan and track study activities and timelines
  • Ensure productive collaborations with other functions in the aligned study team
  • Represent statistics to participate in scientific or technology working groups or cross function initiatives

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new medicines and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medications, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, supported by strategic partnerships and a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's €1.5 billion bond issue strengthens its financial position for future investments.
  • Dupixent's approval for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's 20% Q1 profit growth indicates strong financial performance and market demand.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sarclisa's market share.
  • Potential regulatory delays for tolebrutinib could affect its market entry timeline.
  • Rising R&D costs in immunology and oncology may pressure Sanofi's profitability.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The Sarclisa on-body injector offers a novel delivery method for multiple myeloma treatment.
  • Tolebrutinib targets smoldering neuroinflammation, a key driver of disability in multiple sclerosis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

INACTIVE